Niki BioSolutions, Inc. — Form 8-K
Filed October 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
On October 9, 2026, Niki BioSolutions, Inc. entered into an At-the-Market (ATM) Offering Agreement with H.C. Wainwright & Co., LLC and Brookline Capital Markets (division of Arcadia Securities, LLC) to sell up to $1,396,000 of common stock (par value $0.0001/share) on a continuous basis at market prices via Nasdaq Capital Market. Wainwright acts as exclusive selling agent; Brookline serves as qualified independent underwriter (FINRA Rule 5121). The company pays a 3.0% broker fee on gross proceeds from agent sales, with Wainwright's counsel fees capped at $50,000 per offering cycle. Registration Statement (File No. 333-298608) on Form S-3 became effective October 9, 2026.
Why this rating
ATM offering of ~$1.4M is modest relative to company's ~$18.7M asset base (7.5% of total assets). Standard capital-raising mechanism; no specific use disclosed. Routine disclosure absent material business impact or conditions.
See more from October 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.